Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults.
In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time un...
保存先:
| 出版年: | Antimicrob Agents Chemother |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology (ASM)
1986
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC176405/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3521480/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.29.2.339 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|